M/S. Adarsh Pharmaceutical Works v. Rhugved Pharmaceuticals

When two companies lock horns over the same product in two different courtrooms, the legal system faces a dangerous possibility: contradictory rulings, wasted judicial time, and a brand caught in legal limbo. For founders and IP professionals, the question is not just who is right, but who gets heard first. This Bombay High Court decision offers a powerful reminder that timing, sequencing, and procedural strategy can be just as decisive as the strength of your trademark itself.

M/S. Adarsh Pharmaceutical Works, an established pharmaceutical business, found itself entangled in a trademark dispute over a product it had already taken to court. The company had its own suit pending, complete with an injunction in its favor, concerning the same product at the center of a new controversy. Into this already charged atmosphere stepped Rhugved Pharmaceuticals, which filed a fresh suit alleging passing off in respect of the same product. Adarsh Pharmaceutical moved to stay this second suit, arguing that allowing both to proceed simultaneously would create chaos. When its application for a stay was rejected, the company escalated the matter by filing a writ petition before the Bombay High Court.

Adarsh Pharmaceutical's argument was rooted in procedural clarity. The company contended that since its own suit regarding the same product was already pending and carried an injunction, the subsequent suit filed by Rhugved Pharmaceuticals seeking passing off relief should be stayed under Section 10 of the Code of Civil Procedure. The core of their argument was simple: two courts should not be adjudicating the same subject matter at the same time, especially when one of those courts had already granted interim protection. On the other side, the rejection of the stay application at the lower level suggested that the authorities did not initially see sufficient overlap or justification to halt the second proceedings. The legal friction, therefore, centered on whether the conditions for invoking Section 10 CPC were truly met at this early stage.

The Bombay High Court sided with Adarsh Pharmaceutical. The Court agreed with the petitioner's stance that the parallel proceedings should not be allowed to continue when an earlier suit on the same product was already pending with an injunction in place. The Court directed that the District Judge-12, Nagpur, shall not proceed with Trademark Suit No.3 of 2023 in the interim. By granting this interim relief, the Court effectively acknowledged that Section 10 of the CPC could be invoked to prevent duplicative litigation, even at the initiation stage of the second suit, provided there is a clear overlap in the relief sought. The outcome was mixed in the broader sense: while the immediate relief was granted, the underlying trademark dispute between the two pharmaceutical companies remains unresolved.

For founders, startup leaders, and IP professionals, this case delivers a sharp procedural lesson: if you are already engaged in a trademark or passing off suit and a competitor files a parallel suit on the same product, do not wait for the second suit to gather momentum. Section 10 of the CPC is a powerful tool to stay duplicative proceedings, but it works best when you can demonstrate a clear overlap in subject matter and relief sought. Move quickly, file your stay application early, and be prepared to escalate if the lower court refuses. In IP litigation, being first is not just about branding, it is about controlling the battlefield.